HepAnB

HepAnB is an antiviral medication primarily used in the treatment of hepatitis B virus (HBV) infections. It is part of a class of drugs known as nucleos(t)ide analogues, which work by inhibiting the reverse transcriptase enzyme essential for HBV replication. The active ingredient in HepAnB is tenofovir disoproxil fumarate, a prodrug that is converted in the body to tenofovir, an active metabolite.

HepAnB is prescribed to reduce viral load, improve liver function, and decrease the risk of HBV-related complications such as cirrhosis and hepatocellular carcinoma. It is often used in patients with chronic hepatitis B who require suppression of viral replication. The medication is administered orally, usually once daily, and dosage may vary depending on the patient's condition, age, and renal function.

Common side effects of HepAnB include headache, fatigue, nausea, and dizziness. Serious side effects are rare but can include kidney impairment and lactic acidosis. Regular monitoring of kidney function and liver enzymes is recommended during treatment.

HepAnB is generally well-tolerated and considered a first-line therapy for chronic hepatitis B. Its long-term use can be effective in suppressing the virus, although it does not cure the infection. Resistance can develop over time, making adherence to prescribed therapy critical. As with all antiviral medications, treatment should be supervised by a qualified healthcare professional to ensure safety and efficacy.